title: Depot-medroxyprogesterone acetate: an update.
abstract: OBJECTIVE
  Depo-Provera is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.
  
  
  OBJECTIVE
  Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects. Whether progestins as contraceptives are friends or foes is a questionable matter. In this manuscript, we drive the attention to both usage and side effects Depo-Provera.
  
  
  RESULTS
  Depot-medroxyprogesterone acetate (DMPA) is a highly effective, convenient non-daily hormonal contraceptive option that has been available worldwide for many years. The experience with DMPA provides a large body of long-term data regarding the efficacy and safety of this contraceptive method; this long-term experience has established that the use of DMPA does not increase the risk of cardiovascular events, breast cancer, other gynecologic malignancy, or postmenopausal fracture; however, patients are often more concerned about the relatively immediate effects of contraceptives such as potential changes in menstrual cycle, body weight, and mood disturbances.
  
  
  CONCLUSIONS
  Concerns about such issues may lead to reluctance to initiate therapy or premature discontinuation. Counseling and understanding of women's concerns and experiences using Depo-Provera is important and could help health care providers redesign counseling strategies to improve contraceptive continuation and improve patient adherence.
authors.affiliation: Center for Genetic Engineering and Embryo Culture, Al Azhar University, Cairo 11884, Egypt. sayed.bakry@med.nyu.edu
authors.forename: Sayed
authors.initials: S
authors.lastname: Bakry
authors.forename: Zaher O
authors.initials: ZO
authors.lastname: Merhi
authors.forename: Trudy J
authors.initials: TJ
authors.lastname: Scalise
authors.forename: Mohamad S
authors.initials: MS
authors.lastname: Mahmoud
authors.forename: Ahmed
authors.initials: A
authors.lastname: Fadiel
authors.forename: Frederick
authors.initials: F
authors.lastname: Naftolin
mesh_terms: D000014:Abnormalities, Drug-Induced; D000755:Anemia, Sickle Cell / Q000517:prevention & control; D000818:Animals; D001100:Arachnoiditis / Q000139:chemically induced; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D007774:Lactation / Q000187:drug effects; D008074:Lipoproteins / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D003271:Contraceptive Agents, Female; D008074:Lipoproteins; D017258:Medroxyprogesterone Acetate